Sirtex Medical Limited
(ASX:SRX) has achieved increased dose sales of its SIR-Spheres microspheres targeted radiation therapy for liver cancer.
The biotechnology and medical device company reports dose sales grew 27.1 per cent in the fourth quarter from the third quarter.
Sirtex advises dose sales are a key measure of the company’s business performance and the company has now reported 40 consecutive quarters of dose sales growth.
CEO Gilman Wong says the achievement is a significant milestone and expects the growth to continue.
Sirtex Medical reported a net profit of just over $11 million in the first half of the 2014 financial year.
